Verona pharma reports first quarter 2023 financial results and provides corporate update

Nda submission on schedule for q2 2023 12 abstracts and one symposium expanding on successful phase 3 enhance data to be presented at american thoracic society 2023 strong balance sheet to support commercial launch preparations conference call today at 9:00 a.m. edt / 2:00 p.m.
VRNA Ratings Summary
VRNA Quant Ranking